Apollomics Inc Cl A (APLM)

Dec 20, 2024, 8:00 AM EST - 4 weeks ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 10, 2024, 4:05 PM EST - 5 weeks ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 4, 2024, 4:05 PM EDT - 4 months ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 6:00 AM EDT - 5 months ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 13, 2024, 8:00 AM EDT - 5 months ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Jul 16, 2024, 4:47 PM EDT - 6 months ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 3, 2024, 8:00 AM EDT - 7 months ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apr 25, 2024, 8:30 AM EDT - 9 months ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 10, 2024, 7:00 AM EDT - 10 months ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 28, 2024, 3:57 PM EDT - 10 months ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 7:00 AM EDT - 10 months ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 4, 2024, 7:00 AM EST - 11 months ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Nov 29, 2023, 7:30 AM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 28, 2023, 7:00 AM EST - 1 year ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 16, 2023, 8:30 AM EST - 1 year ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 26, 2023, 8:50 AM EDT - 1 year ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 23, 2023, 8:30 AM EDT - 1 year ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 16, 2023, 6:55 PM EDT - 1 year ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Sep 28, 2023, 4:17 PM EDT - 1 year ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023, 6:21 AM EDT - 1 year ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Apr 26, 2023, 7:45 AM EDT - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO TTOO

Apr 11, 2023, 8:30 AM EDT - 1 year ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Jan 13, 2023, 4:13 PM EST - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Oct 7, 2022, 4:05 PM EDT - 2 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination